Overall Score

Profitability

Margins remain deeply negative, with EBIT margin at -2.42% and net profit margin at -2.36%.

Returns on capital are still poor, with ROIC at -57.4% and ROE at -47.8%.

Gross margin is only 20.1%, leaving limited room to absorb operating costs.

Financial Health

Liquidity is strong, with a current ratio of 7.5x and quick ratio of 6.6x.

Balance sheet leverage remains low, with debt-to-equity at 0.07x and debt-to-assets at 6.1%.

Cash per share of 0.97 and working capital of 55.1M provide near-term flexibility.

Growth

Revenue efficiency remains weak, with asset turnover at 0.19x and revenue per share at 0.32.

Operating cycle is very long at 462.6 days, reflecting slow conversion of inventory and receivables.

No fresh news or metrics indicate an improvement in demand or operating momentum.

Valuation

Valuation remains stretched at 22.4x EV/Sales despite negative EBITDA and free cash flow.

Price-to-book is 5.16x, which is difficult to justify given negative returns on capital.

Negative earnings yield and free cash flow yield indicate the market is still pricing in a turnaround.

Management

Operating discipline appears weak, with SG&A at 190.9% of revenue and R&D at 80.7% of revenue.

Stock-based compensation is high at 81.0% of revenue, adding dilution pressure.

The company is still generating negative operating cash flow, suggesting management has not yet restored execution quality.